MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Non-current Assets
All assets not expected to be converted to cash within one year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 588.3% from a year ago
Total non-current assets stood at $91.56M at the end of Q1 FY2026, up 588.3% from a year earlier and down 40.9% from the prior quarter. Over 3 fiscal years it compounded at +176.1% a year.
Context
- Total non-current assets amounted to 21.9% of total assets at the end of Q1 FY2026, up 9.9 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +588.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 154.84M USD
- Year-over-year change
- +593.9%
- 3-year CAGR
- +176.1%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.84M | +593.9% |
| FY2024 | 2024-12-31 | 22.31M | +185.9% |
| FY2023 | 2023-12-31 | 7.81M | +6.1% |
| FY2022 | 2022-12-31 | 7.36M | — |
Total Non-current Assets vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total non-current assets of $91.56M is the 2nd highest of the 11 companies compared; the peer median is $10.02M.
- Its year-over-year change of +588.3% is the 2nd highest of 10, against a peer median of -1.3%.
- Total non-current assets amounts to 21.9% of total assets for MPLT, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $15.36B | +103156.5% | -0.1% | 16.1% | |
| Mar 2026 | $91.56M | +588.3% | +176.1% | 21.9% | |
| Mar 2026 | $65.48M | +83.3% | +36.3% | 29.0% | |
| Mar 2026 | $48.61M | -46.7% | +40.0% | 17.4% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $22.52M | +6.9% | -4.6% | 2.1% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $12.9M | +16.4% | +245.9% | 2.6% |
| Mar 2026 | $7.13M | -15.0% | +62.2% | 2.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $4.41M | -1.3% | +1044.9% | 1.1% |
| Mar 2026 | $3.04M | -88.2% | -70.3% | 1.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $443K | -76.5% | -76.3% | 0.3% |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $10.02M | -1.3% | +36.3% | 2.3% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.